ten23 health and BD are combining their expertise to prepare the supply chain for the BD Libertas™ portable injector, a subcutaneous delivery solution for self-administered biologic therapies.

Swiss company ten23 health®, a development and manufacturing partner for the pharmaceutical industry and biotech start-ups, announces a partnership with BD (Becton Dickinson) to prepare the supply chain for the BD Libertas™ portable injector. Designed for the subcutaneous administration of high-volume biologic drugs, this device meets the growing demand for self-administered treatments, facilitating the transition from intravenous therapies to more convenient, patient-centered solutions.

An integrated offering from development to GMP production

This partnership combines BD’s platform technology with ten23 health’s integrated services, including process development, aseptic filling, assembly, and quality control. The new “Line 0,” a robotic non-GMP pilot line inaugurated at the Basel facility, allows pharmaceutical companies to test the compatibility and stability of cartridges under representative conditions, reducing time and costs before GMP scale-up.

The Visp site, the hub of sterile commercial production

ten23 health’s GMP production lines in Visp (VIVA1, VIVA2, VIVA3) play a key role in the manufacture of clinical and commercial batches of sterile injectables. Compatible with the equipment on the Basel pilot line, this Valais infrastructure ensures a smooth transition from development to large-scale production for combined drug-device products. This partnership strengthens Valais’ position as a center of biopharmaceutical excellence, capable of attracting new industrial collaborations in the field of modern injectable therapies and self-administration solutions.

Read the full PR (in German) : 262001_PR_BD_Libertas_Partnership_final.DE